( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Administration of nasal Buserelin as compared with subcutaneous Buserelin implant for endometriosis.
One hundred infertile patients with laparoscopically confirmed ovarian endometriosis were treated with either intranasal ( IN ) Buserelin ( Hoechst , AG , Frankfurt am Main , West Germany ) ( 300 micrograms three times a day ) or subcutaneous ( SC ) Buserelin implant ( 6.6 mg Buserelin ) . Serum estradiol was suppressed in the menopausal range in both groups , but the inhibition of the pituitary ovarian axis appeared more profound and consistent in the SC group than in the IN group . Laparoscopic findings proved that the SC Buserelin emerged superior to the IN Buserelin . Indeed , the score of endometriotic lesions and the ovarian cyst diameter were more reduced in the SC group than in the IN group . Moreover , the histologic study showed a lower incidence of active endometriosis and a lower mitotic index of ovarian endometrial epithelium in the SC group than in the IN group . In conclusion , the release of a gonadotropin-releasing hormone agonist by a biodegradable implant achieved better efficacy in reducing endometriotic lesions than the IN mode of administration
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .